Improved glycemic control induces regression of left ventricular mass in patients with type 1 diabetes mellitus

Aepfelbacher, Franz C.; Yeon, Susan B.; Weinrauch, Larry A.; D’Elia, John A.; Burger, Andrew J.

doi:10.1016/s0735-1097(02)80794-x

Cited by 11 publications

(16 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previously, improved left ventricular function has been linked to a reduction in left ventricular mass in type 1 diabetic patients, partially induced by reduced hyperglycaemia (10), but in this study there were no changes in left ventricular mass. This implies that either the improved distribution of insulin or the reduction in glucose levels had a direct influence on the outcome.…”

Section: Discussioncontrasting

confidence: 77%

Changes in glycaemic control are related to the systolic function in type 1 diabetes mellitus

Andersen

Hansen

Christiansen

2007

Scandinavian Cardiovascular Journal

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 77%

Changes in glycaemic control are related to the systolic function in type 1 diabetes mellitus

Andersen

Hansen

Christiansen

2007

Scandinavian Cardiovascular Journal

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4] An increase in prevalence of left ventricular mass (LVM) is observed with each of these conditions. 1,3,4 Reduction in blood pressure (BP), 5 improved DM control, 6,7 and weight loss 8 are associated with regression of LVM.…”

mentioning

confidence: 99%

Effect of Comorbidities and Medications on Left Ventricular Mass Regression After Bariatric Surgery

Syed¹,

Torosoff²,

Rosati³

et al. 2010

J of Clinical Hypertension

View full text Add to dashboard Cite

Hypertension, diabetes, and obesity frequently coexist and significantly contribute to cardiovascular morbidity and mortality. Weight loss in obese individuals has been associated with improved blood pressure control and regression in left ventricular (LV) hypertrophy. The authors investigated the impact of comorbidity and medication on clinical and echocardiographic parameters after weight loss in obese patients. Serial echocardiography and clinical data were collected in 62 patients before bariatric surgery and after 6 months or 10% weight loss. Obese patients with diabetes or hypertension had higher baseline LV mass (LVM) (334AE73 g in hypertension and diabetes vs 252AE97 g in hypertension and 219AE75 g in disease-free patients, P=.003; P=.089 for differences in LVM indexed by height), despite the lack of significant differences in body mass index or systolic blood pressure. There were no significant differences in baseline LVM or LVM index related to the medication used to treat hypertension. After weight loss, patients on b-blocker therapy experienced the most significant LV hypertrophy regression ()76.5AE79.1 g with b-blockers, )17.8AE43.7 g with diuretics, )4.5AE46.6 g with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and )23.1AE50.9 g in not treated patients, overall P=.538; b-blockers vs no therapy P<.005; P=.145 for differences in LVM index). Bariatric surgery, combined with a weight loss program, provide substantial weight and LVM reduction regardless of comorbidities or blood pressure changes. b-Blocker therapy appears to be associated with the greatest LVM regression after weight loss.

show abstract

“…As previously described in type II diabetics [46], this increase seems to be more important in subjects with diabetic nephropathy [55], perhaps in relation to a slight increase of blood pressure [56]. Interestingly, it has been recently described that an improved glycemic control induces regression of LVH in type 1 diabetic patient's [57].…”

Section: Studies In Diabetic Patientsmentioning

confidence: 61%

Plasma Glucose Concentrations and Cardiac Hypertrophy in Essential Hypertension

Stiefel¹,

Villar²,

Navarro-Antolı́n³

2006

CHYR

View full text Add to dashboard Cite

Recently, increasing evidences relate left ventricular mass (LVM) and plasma glucose concentrations in hypertensive patients. In this respect, it has been described a positive and significant relation between LVM and Hemoglobin A1c in essential hypertension. Moreover, hypertensive individuals with diabetes have higher LVM than nondiabetic hypertensive patients with similar blood pressure. It has been also described that an improvement of glycemic control contributes to left ventricular hypertrophy regression in hypertensive patients with type 2 diabetes, and that these changes occurred independently of variation in blood pressure. Finally, we have recently published that "glucose effectiveness" (that represents the ability of glucose per se to effect its own disappearance from plasma independent of dynamic changes from basal insulin) is strongly related to left ventricular mass in subjects with stage 1 hypertension or high-normal blood pressure. The mechanisms by which glucose in itself can induce proliferation and hypertrophy seem to be mainly related to the activation of protein Kinase C pathways. However, it has been also shown that glucose increases intracellular calcium "in vitro" and this increase directly stimulates vascular proliferation and hypertrophy. In the present paper we will review different clinical studies and in vitro experiments, showing that glucose in itself, independently of insulin, can induce vascular proliferation,and cardiac hypertrophy.

show abstract

Improved glycemic control induces regression of left ventricular mass in patients with type 1 diabetes mellitus

Cited by 11 publications

References 21 publications

Changes in glycaemic control are related to the systolic function in type 1 diabetes mellitus

Changes in glycaemic control are related to the systolic function in type 1 diabetes mellitus

Effect of Comorbidities and Medications on Left Ventricular Mass Regression After Bariatric Surgery

Plasma Glucose Concentrations and Cardiac Hypertrophy in Essential Hypertension

Contact Info

Product

Resources

About